AI has begun helping drug companies progress through trials and regulatory submissions, Maggie Fick and Michael Erman of Reuters reports. AI is assisting with finding participants and clinical trial sites as well as drafting documents for regulators. Many drugmakers, including Eli Lilly (LLY) have entered partnerships with Nvidia (NVDA), hoping AI will also improve the success rate of new drugs. Other drug companies in the space also using AI include Novartis (NVS), GSK (GSK), Genmab (GMAB), and Teva Pharmaceutical (TEVA).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Lilly’s Orforglipron Moves Deeper Into Heart-Risk Testing: What Investors Should Know
- Eli Lilly Advances Early-Stage LY4064809 Study, Signaling Steady Pipeline Momentum
- Eli Lilly Advances Remternetug Delivery Options With Completed Device Study
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Novo Nordisk Stock (NVO) Gains on Obesity Pill Demand as Goldman Flags Earnings Upside